Lechenie zlokachestvennykh novoobrazovaniy s mutatsiey gena BRAF V600 s ispol'zovaniem vemurafeniba


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The article presents data from clinical trials evaluating the efficacy of the BRAF inhibitor vemurafenib in patients with various malignant tumors with a mutation in the gene BRAF. It was observed that this agent has high advantages of other anticancer drugs for patients with metastatic skin melanoma. Data of studies among different cohorts of patients with «non-melanoma» cancers showed an activity of vemurafenib in patients with small cell lung cancer, as well as in patients with Langerhans’ cell histiocytosis. The authors emphasize the need to further evaluation of biological factors that influence the success of targeted therapy.

Full Text

Restricted Access

References

  1. Lenoir T. A magic bullet: research for profit and the growth of knowledge in Germany around 1900. J. Minerva. 1988;26(lssue 1):66-88.
  2. Davies, H., Bignell G.R., Cox C., et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417:949-54.
  3. Демидов Л.В., Харкевич Г.Ю., Орлова К.В. Молекулярно-генетическая гетерогенность меланомы кожи и ее значение для разработки индивидуальных подходов к лечению. Фарматека. 2014;17:18-24.
  4. McArthur G., Chapman P., Robert C., Larkin J., Haanen J.B., Dummer R., Ribas A., Hogg D., Hamid O., Ascierto P.A., Garbe C., Testori A., Maio M., Lorigan P., Lebbe C., Jouary T., Schadendorf D., O'Day S.J., Kirkwood J.M., Eggermont A.M., Dreno B., Sosman J.A., Flaherty K.T., Yin M., Caro I., Cheng S., Trunzer K., Hauschild A. Safety and efficacy of vemurafenib in BRAF V600E and BRAF V600K mutationpositive melanoma (BRIM-3): extended follow-up of a phase 3, randomized, open-label study. Lancet Oncology. 2014;15:232-32.
  5. Robert C., Karaszewska B., Schachter J., et al. Two year estimate of overall survival in COMBI-v, a randomized, open-label, phase III study comparing the combination of dabrafenib (D) and trametinib (T) with vemurafenib (Vem) as first-line therapy in patients (pts) with unresect-able or metastatic BRAF V600E/K mutationpositive cutaneous melanoma. Presented at: 2015 European Cancer Congress; September 25-29; Vienna, Austria (Abstract 3301).
  6. Rajagopalan H., Bardelli A., Lengauer C., Kinzler K.W., Vogelstein B., Velculescu V.E. Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature. 2002; 418:934.
  7. Kopetz, S., Desai J., Chan E., Hecht J.R, O'Dwyer P.J., Lee R.J., Nolop K.B., Saltz L. PLX4032 in metastatic colorectal cancer patients with mutant BRAF tumors. J. Clin. Oncol. 2010;28:Abstract 3534.
  8. Hyman D.M., Puzanov I., Subbiah V., Faris J.E., Chau I., BlayJ.Y., Wolf J., Raje N.S., Diamond E.L., Hollebecque A., Gervais R., Elez-Fernandez M.E., Italiano A., Hofheinz R.D., Hidalgo M., Chan E., Schuler M., Lasserre S.F., Makrutzki M., Sirzen F, Veronese ML, Tabernero J, Baselga J. Vemurafenib in Multiple Nonmelanoma Cancers with BRAFV600 Mutations. N. Engl. J. Med. 2015;373(8):726-36.
  9. Имянитов Е.Н. Новая разновидность клинического исследования: "basket trial". http://www.rosoncoweb.ru/news/oncol-ogy/2015/08/31-1/
  10. Protsenko S.A., Semionova A.I., Komarov Y.I., Aleksakhina S.N., Ivantsov A.O., Iyevleva A.G., Imyanitov E.N. BRAF-mutated clear cell sarcoma is sensitive to vemurafenib treatment. Invest New Drugs. 2015;33(5):1136-43.
  11. Samuel J., Macip S., Dyer M.J. Efficacy of vemurafenib in hairy-cell leukemia. N Engl J Med 2014; 370:286-88.
  12. Tiacci E, ParkJ, DeCarolis L, Chung S.S., Broccoli A., Scott S., Zaja F., Devlin S., Pulsoni A., Chung Y.R., не только «мишенью», но и значением этой мишени в канцерогенезе данного новообразования и другими сопутствующими биологическими факторами. Cimminiello M., Kim E., Rossi D., Stone R.M., Motta G., et al. Targeting mutant BRAF in relapsed or refractory hairy-cell leukemia. N. Engl. J. Med. 2015;Sep 9.
  13. Tiacci E., Trifonov V., Schiavoni G., Holmes A, Kern W., Martelli M.P., Pucciarini A., Bigerna B., Pacini R., Wells V.A., Sportoletti P., Pettirossi V., Mannucci R., Elliott O., Liso A., Ambrosetti A., Pulsoni A., Forconi F., Trentin L., Semenzato G., InghiramiG.,Capponi M., DiRaimondo F.,Patti C., Arcaini L., Musto P., Pileri S., Haferlach C., Schnittger S., Pizzolo G., Foa R., Farinelli L., Haferlach T., Pasqualucci L., Rabadan R., Falini B. BRAF mutations in hairy-cell leukemia. N. Engl. J. Med. 2011;364:2305-15.
  14. Myung J.K., Cho H., Park C.K., Kim S.K., Lee S.H., Park S.H. Analysis of the BRAFV600E Mutation in Central Nervous System Tumors. Transl Oncol. 2012;5(6):430-36.
  15. Robinson G.W., Orr B.A., Gajjar A. Complete clinical regression of a BRAF V600E-mutant pediatric glioblastoma multiforme after BRAF inhibitor therapy. BMC Cancer. 2014;14:258.
  16. Nicolaides T.P., Li H., Solomon D.A., Hariono S., Hashizume R., Barkovich K., Baker S.J., Paugh B.S., Jones C., Forshew T., Hindley G.F., Hodgson J.G., Kim J.S., Rowitch D.H., Weiss W.A., Waldman T.A., James C.D. Targeted Therapy for BRAF(V600E) Malignant Astrocytoma. Clin. Cancer Res. 2011;17(24):7595-604.
  17. Инструкция по медицинскому применению препарата, ЛП-002271.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies